Skip to main content

Table 3 Summary of major published studies of 125I brachytherapy for gliomas

From: Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma

Study

No. of patients

Type of gliomas

Implanted dose (Gy)

Median survival

B. Suchorska et al. [20]

99(primary)

73(recurrence)

Primary and recurrence anaplastic glioma WHOIII

60(primary), 60(recurrence)

28.9 months(primary),

21.4 months (recurrence)

David A. Larson et al. [21]

38

Progressive or recurrent glioblastoma multiforme

300 (at 5-mm depth)

52 weeks

Philipp Kickingereder et al. [22]

103 (primary)

98(recurrence)

Primary and recurrent glioblastoma

60

11.1 months(primary)

10.4(recurrence)

Patrick Y.Wen et al. [23]

56

Glioblastoma

50

22 months (reoperation)

13 months (no further surgery)

Berstein et al. [24]

23

Malignant glioma

60–70

14 months